Association between inhaled corticosteroid therapy for COPD and diabetes onset and progression

15:30 - 15:45

Speaker: Konstantinos Kostikas

ICS withdrawal and exacerbation risk by GOLD 2017 report: Post hoc analysis of the WISDOM trial

15:45 - 16:00

Speaker: Peter Frith

Indacaterol/glycopyrronium vs single long-acting muscarinic antagonist in long-acting bronchodilator-naive COPD patients: Pooled analysis

16:00 - 16:15

Speaker: Konstantinos Kostikas

Antibody response to influenza vaccine in chronic obstructive pulmonary disease (COPD)

16:15 - 16:30

Speaker: Natale Snape

Persistent blood eosinophilia and COPD exacerbation risk after ICS withdrawal from triple therapy in the SUNSET study

16:30 - 16:45

Speaker: Konstantinos Kostikas

Careful use of prophylactic intermittent and continuous macrolides reduces exacerbation rates in COPD: Systematic review and meta-analysis

16:45 - 17:00

Speaker: Samantha Herath